Prestige Biologics Co Ltd
KOSDAQ:334970
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prestige Biologics Co Ltd
Accounts Receivables
Prestige Biologics Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Prestige Biologics Co Ltd
KOSDAQ:334970
|
Accounts Receivables
₩1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Receivables
₩2T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Accounts Receivables
₩1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accounts Receivables
₩80.8m
|
CAGR 3-Years
332%
|
CAGR 5-Years
141%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Receivables
₩37.2B
|
CAGR 3-Years
64%
|
CAGR 5-Years
81%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Receivables
₩59.1B
|
CAGR 3-Years
2 371%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prestige Biologics Co Ltd
Glance View
Prestige Biologics Co., Ltd. engages in research, development, and supplying of pharmaceutical products. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 199 full-time employees. The company went IPO on 2021-03-11. The firm mainly engages in the contract manufacturing service business that produces and supplies biopharmaceuticals; and contract development service business that provides development services including cell culture process and purification process.
See Also
What is Prestige Biologics Co Ltd's Accounts Receivables?
Accounts Receivables
1.3B
KRW
Based on the financial report for Dec 31, 2025, Prestige Biologics Co Ltd's Accounts Receivables amounts to 1.3B KRW.
What is Prestige Biologics Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
-67%
Over the last year, the Accounts Receivables growth was -67%.
